Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serum Collection for Fluzone 2019-2020
NCT04109222Phase 4Completed
- Sponsor
- Sanofi
- Start
- Sep 2019
- Primary completion
- Dec 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated) and trivalent inactivated influenza vaccine high-dose in influenza (3 arms), sponsored by Sanofi. Primary endpoints: Number of Participants Aged 6 Months to < 9 Years Who Provided Serum Samples for Analysis at Day 56 and Number of Participants Aged >= 65 Years Who Provided Serum Samples for Analysis at Day 21. Started Sep 2019; status: completed.
02
Drugs
Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated)trivalent inactivated influenza vaccine high-dose
03
Conditions
influenza
Beyond the preview
Go deeper on NCT04109222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04109222.